IMTX

Immatics N.V.

12.84 USD
-0.18 (-1.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immatics N.V. stock is up 18.78% since 30 days ago. The next earnings date is Aug 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 3 June’s closed higher than May. In the last 4 Unusual Options Trades, there were 1 PUT, 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Apr 19:51 17 Jan, 2025 7.50 PUT 360 330
14 May 14:04 17 Jan, 2025 12.50 CALL 250 561
24 May 18:55 17 Jan, 2025 12.50 CALL 525 975
07 Jun 19:57 19 Jul, 2024 15.00 CALL 319 813

About Immatics N.V.

Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.